Results 51 to 60 of about 26,399 (169)

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells [PDF]

, 2019
During antiretroviral therapy (ART), human immunodeficiency virus type 1 (HIV-1) persists as a latent reservoir in CD4+ T cell subsets in central memory (TCM), transitional memory (TTM), and effector memory (TEM) CD4+ T cells.
Yuan, Sally, Bebin-Blackwell, Anne-Gaelle, Deeks, Steven G, Barnard, Richard, Sékaly, Rafick-Pierre, Hazuda, Daria, Chomont, Nicolas, Brehm, Jessica H, Ribeiro, Susan Pereira, Miller, Michael, Talla, Aarthi, Kulpa, Deanna A   +11 more
core   +1 more source

CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T cells

iScience
Summary: HIV-1 latency is regulated by chromatin modifying enzymes, and histone deacetylase inhibitors (HDACi) cause reactivation of provirus expression.
Riley M. Horvath, Ivan Sadowski
doaj   +1 more source

DataSheet_1_Natural killer cells induce HIV-1 latency reversal after treatment with pan-caspase inhibitors.pdf

, 2022
The establishment of a latency reservoir is the major obstacle for a cure of HIV-1. The shock-and-kill strategy aims to reactivate HIV-1 replication in HIV -1 latently infected cells, exposing the HIV-1-infected cells to cytotoxic lymphocytes.
Robert van Domselaar (9436448), George Gourgi (14222852), Luca Love (12800641), Joana Furtado Milão (14222849), Lukas Derhaschnig (14222855), J. Peter Svensson (8378355), Anders Sönnerborg (153581)   +6 more
core   +1 more source

Human Immunodeficiency Virus-1 Latency Reversal via the Induction of Early Growth Response Protein 1 to Bypass Protein Kinase C Agonist-Associated Immune Activation

Frontiers in Microbiology, 2022
Human Immunodeficiency Virus-1 (HIV) remains a global health challenge due to the latent HIV reservoirs in people living with HIV (PLWH). Dormant yet replication competent HIV harbored in the resting CD4+ T cells cannot be purged by antiretroviral ...
Lilly M. Wong, Dajiang Li, Yuyang Tang, Gema Méndez-Lagares, George R. Thompson, Dennis J. Hartigan-O’Connor, Satya Dandekar, Guochun Jiang, Guochun Jiang   +8 more
doaj   +1 more source

Neurotoxicity with high dose disulfiram and vorinostat used for HIV latency reversal [PDF]

, 2022
OBJECTIVE: To examine whether administering both vorinostat and disulfiram to people with HIV (PWH) on antiretroviral therapy (ART) is safe and can enhance HIV latency reversal.
Burger, D, Evans, VA, Heck, CJS, Lau, JSY, Zuck, P, Dantanarayana, A, Fisher, K, Rasmussen, TA, Wu, G, Zetterberg, HH, Lewin, SR, Tennakoon, S, Blennow, K, Hagenauer, M, Zerbato, JM, Mcmahon, JH, Howell, BJ, Gisslen, M, Palmer, S, Symons, J, Chang, J, Solomon, A, Lee, S, Bumpus, N   +23 more
core  

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment

Journal of Nanobiotechnology, 2019
Background The major obstacle impeding human immunodeficiency virus-1 (HIV-1) eradication in antiretroviral treatment (ART) treated HIV-1 subjects is the establishment of long-lived latently infected resting CD4+ T cells. Due to the fact that no drug has
Ignacio Relaño-Rodríguez, Raquel Juárez-Sánchez, Carolina Pavicic, Eduardo Muñoz, Maria Ángeles Muñoz-Fernández   +4 more
doaj   +1 more source

Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems. [PDF]

PLoS ONE, 2016
CRISPR/Cas9 technology is currently considered the most advanced tool for targeted genome engineering. Its sequence-dependent specificity has been explored for locus-directed transcriptional modulation.
Julia K Bialek, Gábor A Dunay, Maike Voges, Carola Schäfer, Michael Spohn, Rolf Stucka, Joachim Hauber, Ulrike C Lange   +7 more
doaj   +1 more source

Editorial Commentary: Reversing Latency in HIV-Infected Patients [PDF]

Clinical Infectious Diseases, 2013
The inability of combination antiretroviral treatment (cART) to eradicate human immunodeficiency virus (HIV) infection has renewed scientific interest in curative strategies [1]. The primary barrier preventing eradication of HIV by cART is a pool of long-lived latently infected cells of which memory CD4 + T cells appear to be the most important.
openaire   +2 more sources

Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents [PDF]

AIDS, 2020
Objective: While latently HIV-infected cells have been described in the blood, it is unclear whether a similar inducible reservoir exists in the gut, where most HIV-infected cells reside. Tissue-specific environments may contribute to differences in the mechanisms that govern latent HIV infection and amenability to reactivation.
Telwatte, Sushama, Kim, Peggy, Chen, Tsui-Hua, Milush, Jeffrey M, Somsouk, Ma, Deeks, Steven G, Hunt, Peter W, Wong, Joseph K, Yukl, Steven A   +8 more
openaire   +4 more sources

BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells

Journal of Virology
HIV cure strategies that aim to induce viral reactivation for immune clearance leverage latency reversal agents to modulate host pathways which directly or indirectly facilitate viral reactivation.
Anne-Marie W. Turner, Frances M. Bashore, Shane D. Falcinelli, Joshua A. Fox, Alana L. Keller, Anthony D. Fenton, Renee F. Geyer, Brigitte Allard, Jennifer L. Kirchherr, Nancie M. Archin, Lindsey I. James, David M. Margolis   +11 more
doaj   +1 more source